TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04561401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated Transcranial Magnetic Stimulation (rTMS)
Description: rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Pain Rehabilitation Program (IPRP)
Description: The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Pain Rehabilitation Program (IPRP)
Description: The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
Study: NCT04138407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seated Tai Chi
Description: Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair

Intervention type: OTHER
Group type: OTHER
Intervention: Usual rehabilitation exercise
Description: Regular rehabilitation exercise used in participating hospital
Study: NCT00974714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Oral L-arginine 2 g twice a day for 14 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo 2 g twice a day for 14 weeks
Study: NCT02201303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Powdered form for in-vitro administration to blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CXCL1
Description: Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CXCL1
Description: Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
Study: NCT02967367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jawbone sleep tracker
Description: During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings sleep tracker
Description: During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
Study: NCT02952833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sodium chloride solution.
Study: NCT02301871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Gene's Health and Wellness
Description: The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching and Cervical non thrust manipulation
Description: conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
Study: NCT02952833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sodium chloride solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sodium chloride solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
Study: NCT01777776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
Study: NCT02788890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling without LA
Description: The patient will undergo a supragingival scaling procedure without local anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple restoration under LA
Description: The patient will undergo a simple dental restoration procedure under local anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple exodontia under LA
Description: The patient will undergo a simple dental extraction procedure under local anesthesia
Study: NCT01481064

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multifaceted approach
Description: Audit and feedback, educational outreach visits, and patient-mediated interventions.
Study: NCT04416009

Intervention type: DEVICE
Intervention: NİCaS
Description: whole body bioimpedence method

Intervention type: DEVICE
Intervention: NİCaS
Description: whole body bioimpedence method
Study: NCT05599373

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Active Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS over bilateral dorsolateral prefrontal cortex
Description: Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
Study: NCT06323655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Control Placebo
Description: oral capsule
Study: NCT01777776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
Study: NCT06323655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Control Placebo
Description: oral capsule
Study: NCT01777776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
Study: NCT06323655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tasimelteon Placebo
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tasimelteon Placebo
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: oral capsule
Study: NCT04348760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rotation Diet
Description: Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
Study: NCT03950531

Intervention type: OTHER
Intervention: No intervention
Study: NCT01698723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01345266

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inhalation Profiling
Description: All subects recieve Inhaltion Profiling there are no interventions.
Study: NCT03252808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: 1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: 1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: 1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
Study: NCT01214382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Single dose sertraline 100 mg, tablet and solution
Study: NCT02748395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00489411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Given orally
Study: NCT02748395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT02416154

Intervention type: PROCEDURE
Intervention: Reproductive tract and blood sampling
Description: Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
Study: NCT04371965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
Study: NCT03593044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% concentration atropine drops
Description: One drop of 0.01% concentration atropine in each eye at night for seven days.
Study: NCT00489411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT04136730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based
Description: Resistance exercise carried out unsupervised at home
Study: NCT04337827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scans
Description: 2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
Study: NCT04037826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475
Description: L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
Study: NCT00890110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous renal cell vaccine based on DNP modified cells
Description: Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
Study: NCT03320720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Treatment
Description: Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
Study: NCT03772262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: goldenseal
Description: Oral 500 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution
Study: NCT04037826

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00802295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotrophins
Description: Administration of standard ovarian stimulation protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dosis Gonadotrophin
Study: NCT03772262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution
Study: NCT04322929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Oral Tablet
Description: Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
Study: NCT03772262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: Oral syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: Oral syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Oral Tablet
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Oral Tablet
Description: Oral tablet
Study: NCT04279535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Ascorbic Acid
Description: Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Ascorbic Acid
Description: Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
Study: NCT01574066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest CT-scan
Description: Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
Study: NCT00475566

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynalink®-E everolimus-eluting peripheral stent
Description: Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynalink®-E, everolimus-eluting peripheral stent
Description: Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
Study: NCT00940758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP02
Description: Dose escalation: 50-100 mg/m2 biweekly
Study: NCT01694056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy protein diet
Description: 4 weeks high protein diet (20 en%) with 25gr of soy protein per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: 4 weeks high mixed protein diet (20 en%)
Study: NCT04265794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H2GO!
Description: Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
Study: NCT03730623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
Study: NCT00881374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Infantile (Lactic Acid)
Study: NCT01143129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single dose (1 mg/kg) at start of cardiac surgical procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
Study: NCT02068001

Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass